Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3481]

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR...

Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC ( Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China )

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients...

Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors ( Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain )

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher...

Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity ( Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada )

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant...

Dr Janice Mehnert - NYU Langone Health, New York, USA

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival ( Dr Janice Mehnert - NYU Langone Health, New York, USA )

Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive...

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive gastric cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in...

Dr Inge Marie Svane - Copenhagen University Hospital, Copenhagen Denmark

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma ( Dr Inge Marie Svane - Copenhagen University Hospital, Copenhagen Denmark )

Zanzalintinib plus atezolizumab improves survival in refractory mCRC

Dr Anwaar Saeed - University of Pittsburgh, Pittsburgh, USA

$Zanzalintinib plus atezolizumab improves survival in refractory mCRC ( Dr Anwaar Saeed - University of Pittsburgh, Pittsburgh, USA )$

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR...

Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC ( Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA )

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource...

Dr Atul Batra - All India Institute Of Medical Sciences Delhi, New Delhi, India

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings ( Dr Atul Batra - All India Institute Of Medical Sciences Delhi, New Delhi, India )

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2...

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2−...

Prof Stephen Johnston - The Royal Marsden, London, UK

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer ( Prof Stephen Johnston - The Royal Marsden, London, UK )

More from ecancer